Topics:
Genitourinary Cancers • Medical Oncology
Would you prefer FGFR inhibitor or second line immunotherapy in a patient with metastatic urothelial cancer of the bladder with FGFR mutation?
Retrospective data show very low response rate of immunotherapy in FGFR mutated patients.
Answer from: Medical Oncologist at Community Practice
I would clearly prefer immunotherapy specifically with the use of pembrolizumab. I would measure the PDL1 CPS expression, where the impact is much greater. Phase 3 data clearly shows significantly improved survival compared to chemotherapy or BSC. This is the first positive trial in the second-line ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Ideally clinical trial is the preferred option. There are many trials including THOR phase 3 trial comparing erdafitinib vs chemoTx and erdafitinib vs pembrolizumab. In the absence of trials, erdafitinib seems a very attractive 2nd line option for patients with FGFR activating mutation or fusion, es...
Comments
Medical Oncologist at ZNA Jan Palfijn
Thank you! He will be screened for THOR study and ...
Thank you! He will be screened for THOR study and ...